Page 30 - மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SILVER SPRING, Md., March 5, 2021 /PRNewswire/ Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2. Today s authorization further underscores the FDA s commitment to innovation in test development, said Jeff Shuren, M.D., J.D., director of FDA s Center for Devices and Radiological Health. The T-Detect COVID Test is a novel technology that assesses the T cell immune response to COVID-19. Information and scientific data that deepen our understanding of SARS-CoV-2 remain important keys to get ahead of this global pandemic.

Lauren jei mccarthyJeff shurenClinical laboratory improvement amendmentsRadiological healthAdaptive biotechnologies corporationDrug administrationUs food and drug administrationலாரன் ஜே ம்க்கார்தீமருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள்கதிரியக்கவியல் ஆரோக்கியம்மாற்றி அமைக்கத்தக்க உயிரி தொழில்நுட்பங்கள் நிறுவனம்